PharmaEssentia: Q1 2025 delivered record revenue and profit growth, with robust cash flow and global expansion
Займёт меньше минуты
Q1 2025 saw revenue nearly double and net income surge 282% year-over-year, driven by strong product sales and improved margins. Major arbitration with AOP saw mixed outcomes, while significant investments continue in R&D and global expansion.
Original document: PharmaEssentia Corp. [6446] Interim report — May. 29 2025
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr